172 related articles for article (PubMed ID: 12482789)
1. Mode of death in heart failure: findings from the ATLAS trial.
Poole-Wilson PA; Uretsky BF; Thygesen K; Cleland JG; Massie BM; Rydén L;
Heart; 2003 Jan; 89(1):42-8. PubMed ID: 12482789
[TBL] [Abstract][Full Text] [Related]
2. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
Packer M; Poole-Wilson PA; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Rydén L; Thygesen K; Uretsky BF
Circulation; 1999 Dec; 100(23):2312-8. PubMed ID: 10587334
[TBL] [Abstract][Full Text] [Related]
3. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival.
Massie BM; Armstrong PW; Cleland JG; Horowitz JD; Packer M; Poole-Wilson PA; Rydén L
Arch Intern Med; 2001 Jan; 161(2):165-71. PubMed ID: 11176729
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial.
Rydén L; Armstrong PW; Cleland JG; Horowitz JD; Massie BM; Packer M; Poole-Wilson PA
Eur Heart J; 2000 Dec; 21(23):1967-78. PubMed ID: 11071803
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China.
Liu X; Yu H; Pei J; Chu J; Pu J; Zhang S
Heart Lung Circ; 2014 Sep; 23(9):818-26. PubMed ID: 24881031
[TBL] [Abstract][Full Text] [Related]
6. [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Gronda E; Mangiavacchi M; Andreuzzi B; Municinò A
Ital Heart J Suppl; 2001 Dec; 2(12):1278-83. PubMed ID: 11838348
[TBL] [Abstract][Full Text] [Related]
7. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Pitt B; Poole-Wilson P; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
J Card Fail; 1999 Jun; 5(2):146-54. PubMed ID: 10404354
[TBL] [Abstract][Full Text] [Related]
8. Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group.
Sculpher MJ; Poole L; Cleland J; Drummond M; Armstrong PW; Horowitz JD; Massie BM; Poole-Wilson PA; Ryden L
Eur J Heart Fail; 2000 Dec; 2(4):447-54. PubMed ID: 11113723
[TBL] [Abstract][Full Text] [Related]
9. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
10. Association of blood pressure and its evolving changes with the survival of patients with heart failure.
Grigorian-Shamagian L; Gonzalez-JuAnatey JR; Vazquez R; Cinca J; Bayes-Genis A; Pascual D; Fernandez-Palomeque C; Bardaji A; Almendral J; Nieto V; Macaya C; Jimenez RP; de Luna AB;
J Card Fail; 2008 Sep; 14(7):561-8. PubMed ID: 18722321
[TBL] [Abstract][Full Text] [Related]
11. Ambulatory blood pressure monitoring, 2D-echo and clinical variables relating to cardiac events in ischaemic cardiomyopathy following cardioverter-defibrillator implantation.
Antonini L; Pasceri V; Mollica C; Ficili S; Poti G; Aquilani S; Santini M; La Rocca S
J Cardiovasc Med (Hagerstown); 2011 May; 12(5):334-9. PubMed ID: 21487343
[TBL] [Abstract][Full Text] [Related]
12. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis.
Odutayo A; Wong CX; Hsiao AJ; Hopewell S; Altman DG; Emdin CA
BMJ; 2016 Sep; 354():i4482. PubMed ID: 27599725
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic therapy in heart failure.
Eckardt L; Haverkamp W; Breithardt G
Heart Fail Monit; 2002; 2(4):110-9. PubMed ID: 12634885
[TBL] [Abstract][Full Text] [Related]
14. The influence of dose of angiotensin I-converting enzyme inhibitor on systolic blood pressure variability in heart failure: a substudy of the Assessment of Treatment with Lisinopril and Survival in heart failure (ATLAS) trial.
Giles TD; Kerut EK; Roffidal LE; Jones R; Given MB; Hutchinson H; Tresznewsky O
Blood Press Monit; 2001 Apr; 6(2):81-4. PubMed ID: 11433128
[TBL] [Abstract][Full Text] [Related]
15. Causes of death in the ATLAS study: effects of high-dose ACE inhibitors.
Cleland JG
Int J Clin Pract Suppl; 1999 Apr; 100():19-20. PubMed ID: 10658295
[No Abstract] [Full Text] [Related]
16. [Clinical study of the month. The ATLAS study].
Kulbertus H
Rev Med Liege; 1999 Dec; 54(12):952-4. PubMed ID: 10686803
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs' Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure).
Bilchick KC; Fetics B; Djoukeng R; Fisher SG; Fletcher RD; Singh SN; Nevo E; Berger RD
Am J Cardiol; 2002 Jul; 90(1):24-8. PubMed ID: 12088774
[TBL] [Abstract][Full Text] [Related]
18. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis.
Khan MS; Fonarow GC; Ahmed A; Greene SJ; Vaduganathan M; Khan H; Marti C; Gheorghiade M; Butler J
Circ Heart Fail; 2017 Aug; 10(8):. PubMed ID: 28790052
[TBL] [Abstract][Full Text] [Related]
19. Denervated Myocardium Is Preferentially Associated With Sudden Cardiac Arrest in Ischemic Cardiomyopathy: A Pilot Competing Risks Analysis of Cause-Specific Mortality.
Fallavollita JA; Dare JD; Carter RL; Baldwa S; Canty JM
Circ Cardiovasc Imaging; 2017 Aug; 10(8):. PubMed ID: 28794139
[TBL] [Abstract][Full Text] [Related]
20. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.
Cleland JG; Erhardt L; Murray G; Hall AS; Ball SG
Eur Heart J; 1997 Jan; 18(1):41-51. PubMed ID: 9049514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
